Medicus Pharma Expands Basal Cell Carcinoma Trial to Asia-Pacific

Medicus Pharma Ltd., a biopharmaceutical company that specializes in skin cancers, promotes the application of innovative treatments has announced its partnership with Swanielle Inc., the most sought-after healthcare consulting firm. It has the vision that the partnership may help in the Asia-Pacific expansion of Medicus’ Phase 2 clinical trial on the SKNJCT-003 drug for BCC treatment. Though based mainly in the United States, Swanielle will use its knowledge of Southeast Asia to seek potential partner pharmaceutical corporations with a goal to align with Medicus’s mission of adding more patients to the realm of patient access to life-saving medicines and to expedite clinical drug development around the world.

The Phase 2 trial is currently on process in nine clinical places in the US with only 15 of the required 60 patients enrolled. Medicus plans to report the first interim analysis in 1Q2025, which upon successful outcome should provide sufficient evidence to support a PMA submission to the FDA. The company is yet to approach the FDA for an interim meeting in Q2 2025 to plead for the trials to be escalated to the next level. Therefore, Medicus decided on strategic growth and partnership targeting that is aimed at the fast-paced acceleration of the company’s clinical program and the overall need to address the increase in skin cancer cases throughout the world.